Chirag Patel: Great. So three launches, which check marks the first requirement for that. As we build the, I mean, I would take it that a little bit in 2007 we started building Amneal Generics business, it took 10-years to get to top five. So we do expect this as also a 10-years journey, but every year, there’s a lot of progress. So the second strategy after these licensing, obviously we are working on a few more licensing only from the proven companies. And then we would — we’re working on vertically being integrated for some of the products to have our own R&D. So we would bring that in-house, our own manufacturing, we love U.S. manufacturing and couple that with probably India manufacturing, as well for the emerging markets or any other markets we can ship from India as well or even U.S. So multiple approaches, so we should be all set — plan is to smooth at starting next year.
and continue to add and that brings, obviously, we’ll bring the pipeline. And as Chintu mentioned earlier, just like what we did in the generics market is we want to be many in cost to market. So first biosimilar second at most, we’re not touching where we would be a eight square and there are a lot of missions within immunology, within oncology or weaker outside of those two as well. And the commercial infrastructure is kickass. We have one of the best and keep building it. That’s something we made really well on generics business, we became a trusted partner for our customers, even though they kept consolidating, we still love them, and we’re still — we enjoy probably the top position with them for all the buy groups. And here, we’re doing same thing with oncology groups, hospitals, the cancer centers, we’re just likeable company.
So — and we are recalling others, they can count on our supply they can count on. So with all that and taking it global as well from the beginning, very excited to build and very committed to build this business probably, because we know how it’s going to play out over three, five, seven years, you will see the companies like us and Teva and Sandoz playing in this and then obviously has a division and always two large Korean players. But you won’t see branded companies playing in this much at all. So it leaves more, as I called it earlier, the next 20-year of affordable medicine business, and those are the companies that actually going to be one of the leaders there going forward. Harsher, you want to add anything if I missed.
Harsher Singh: Hey, Balaji I think our focus is a bit more buy and build and it is — then is sort of Part B in the context of our pipeline and what we’re chasing. We do think those markets are more interesting. So that’s how you should think about pipeline though we’re not public on it right now.
Chirag Patel: Thank you.
Operator: Ladies and gentlemen, we currently have no further questions. I would now like to hand over to Chirag Patel for final remarks.
Chirag Patel: Thank you, everyone. Have a great day.
Operator: Ladies and gentlemen, this concludes today’s call. Thank you for joining. You may now disconnect your lines. Thank you.
